Literature DB >> 11994860

Strategies to treat protein-losing enteropathy.

Jack Rychik1, Thomas L Spray.   

Abstract

Protein-losing enteropathy (PLE), excessive serum protein loss within the gastrointestinal tract, after Fontan operation is a poorly understood disorder. Reported to occur anywhere from weeks to years after Fontan operation, there are no identifiable risk factors for its development, and its clinical manifestations vary widely from significant morbidity and mortality to mild-to-moderate hypoproteinemia with minimal functional impairment. Treatment strategies, tailored to the severity of the disease, include symptomatic relief with diuretics and supplemental protein, attempts at halting intestinal protein leak using steroids or heparin, and alteration of cardiovascular physiology via fenestration creation, atrial pacing, or heart transplantation. A better understanding of the pathophysiology of PLE will allow the development of more effective treatment modalities. We hypothesize an abnormality of local intestinal circulation in patients with PLE that may be related to low cardiac output. Compensatory flow redistribution takes place under conditions of low cardiac output. We studied superior mesenteric artery flow using Doppler ultrasound in 40 patients after Fontan operation, 13 of whom had clinical signs of PLE, and compared them with 25 normal control patients. Diastolic velocities were lower in Fontan subjects, and the ratio of systolic-to-diastolic velocities and the resistance index were higher in Fontan patients compared with the control group. Patients with PLE after Fontan operation had higher systolic-to-diastolic velocities and resistance index than patients with Fontan and no active PLE. However, subjects with Fontan circulation but without PLE had higher indices of mesenteric resistance than the normal controls, suggesting an abnormality of the mesenteric circulation even in those without overt signs of PLE. It is plausible to postulate that activation of the renin-angiotensin system with increased levels of circulating angiotensin II may be responsible for the increase in mesenteric vascular resistance seen after Fontan operation, thereby placing these patients at risk for development of PLE. Copyright 2002 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994860     DOI: 10.1053/pcsu.2002.31498

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu        ISSN: 1092-9126


  14 in total

1.  Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation.

Authors:  S Chakrabarti; B R Keeton; A P Salmon; J J Vettukattil
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

2.  Evidence of Systemic Absorption of Enteral Budesonide in Patients with Fontan-Associated Protein-Losing Enteropathy.

Authors:  Richard Ogden Roberts; Michael V Di Maria; Dania Brigham; Stephanie Hsu
Journal:  Pediatr Cardiol       Date:  2019-11-09       Impact factor: 1.655

3.  Mechanisms of systemic adaptation to univentricular Fontan conversion.

Authors:  Cynthia D Myers; Kimberly Ballman; Lindsay E Riegle; Kelly D Mattix; Kenneth Litwak; Mark D Rodefeld
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05-18       Impact factor: 5.209

4.  Prevalence of Subclinical Enteric Alpha-1-Antitrypsin Loss in Children with Univentricular Circulation Following Total Cavopulmonary Connection.

Authors:  Colm R Breatnach; Aoife Cleary; Terence Prendiville; Kathleen Crumlish; Helene Murchan; Colin J McMahon
Journal:  Pediatr Cardiol       Date:  2017-09-06       Impact factor: 1.655

5.  Creation and enlargement of atrial defects in congenital heart disease.

Authors:  G R Veldtman; G Norgard; H Wåhlander; Y Garty; O Thabit; B W McCrindle; K J Lee; L N Benson
Journal:  Pediatr Cardiol       Date:  2005 Mar-Apr       Impact factor: 1.655

6.  A viable therapeutic option: mechanical circulatory support of the failing Fontan physiology.

Authors:  Amy L Throckmorton; Sergio Lopez-Isaza; Emily A Downs; Steven G Chopski; James J Gangemi; William Moskowitz
Journal:  Pediatr Cardiol       Date:  2013-02-15       Impact factor: 1.655

Review 7.  Medical management of the failing Fontan.

Authors:  N S Ghanayem; S Berger; J S Tweddell
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

8.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Ascites secondary to indolent pacemaker infection in a Fontan patient.

Authors:  C Tania Condurache; Christopher L Johnsrude; Kristina Bryant; Michael R Recto
Journal:  Tex Heart Inst J       Date:  2008

10.  Pneumatically-driven external pressure applicator to augment Fontan hemodynamics: preliminary findings.

Authors:  Amy L Throckmorton; Sonya S Bhavsar; Steven G Chopski; William B Moskowitz
Journal:  Transl Pediatr       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.